Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/cancers9050041 http://scihub22266oqcxt.onion/10.3390/cancers9050041 C5447951!5447951!28448462     free     free     free       Cancers+(Basel) 2017 ; 9 (5): ä Nephropedia Template TP {{tp|p=28448462|t=2017. Targeting the ATR-CHK1 Axis in Cancer Therapy |pdf=|usr=}}{{28448462}} gab.com Text Targeting the ATR-CHK1 Axis in Cancer Therapy JO: Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28448462 #FOAvip Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented. Twit Text FOAVip Targeting the ATR-CHK1 Axis in Cancer Therapy ????Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28448462 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28448462 #FOAvip English Wikipedia <ref>{{Cite pmid|28448462}}</ref> Targeting the ATR-CHK1 Axis in Cancer Therapy #MMPMID28448462 Rundle S; Bradbury A; Drew Y; Curtin NJ Cancers (Basel) 2017[May]; 9 (5): ä PMID28448462show ga Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented. äTargeting the ATR-CHK1 Axis in Cancer Therapy (epmc).pdf DeepDyve Pubget Overpricing